JCCVS
Journal of Cardiology & Cardiovascular Surgery

Journal of Cardiology & Cardiovascular Surgery scientific, open-access, double-blind peer-reviewed journal covering a wide spectrum of topics in cardiology and cardiovascular surgery.

eISSN: 2980-1397
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The effect of ranolazine on erectile dysfunction in coronary artery disease patients
Abstract
Aims: Erectile dysfunction (ED) and coronary artery disease (CAD) are disorders with similar pathophysiology and the prevalence of ED may be as high as 75% in cardiovascular patients. Ranolazine is a second line therapy in CAD patients with angina. It inhibits the late sodium current in cardiomyocytes. It also has positive effects on endothelial dysfunction which is a common disruption on both CAD and ED. We aim to evaluate the effect of ranolazine on ED in CAD patients with angina complaints.
Methods: A total of 37 CAD patients were included for the study. Ranolazine was started to patients with angina symptoms. Sexual Health Inventory for men (SHIM) questionnaire was used to evaluate the status of ED. The questionnaire was applied to patients before the start and at the 6th month of ranolazine treatment.
Results: The SHIM scores of each question did not change significantly after the follow up period (p>0.05). The total SHIM score at the beginning was 10.7 ± 5.4 and after 6 months the SHIM score was 10.7 ± 6.3 and the difference was statistically insignificant (p=0.757). The changes in the SHIM classes were not statistically significant (p=0.454).
Conclusion: Ranolazine does not have positive or negative effects on ED at CAD patients with angina pectoris. Further studies with larger patient population must be done to confirm the results of the study.

Keywords : Coronary artery disease, erectile dysfunction, ranolazine, sexual health Inventory for men questionnaire

Download Article


1. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130-171. doi:10.1111/jsm.12023
2. Meller SM, Stilp E, Walker CN, et al. The link between vasculogenic erectile dysfunction, coronary artery disease, and peripheral artery disease: role of metabolic factors and endovascular therapy. J Invasive Cardiol. 2013;25(6):313-319.
3. Raheem OA, Su JJ, Wilson JR, et al. The association of erectile dysfunction and cardiovascular disease: a systematic critical review. Am J Mens Health. 2017;11(3):552-563. doi:10.1177/1557988316630305
4. Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170(2 Pt 2)S46-S50. doi:10.1097/01.ju.0000075055.34506.59
5. Montorsi F, Salonia A, Deho F, et al. Pharmacological management of erectile dysfunction. BJU Int. 2003;91(5):446-454. doi:10.1046/j.1464-410x.2003.04093.x
6. Sood R, Sharma D, Goel H, et al. The correlation between erectile dysfunction and metabolic syndrome in an Indian population: a cross-sectional observational study. Arab J Urol. 2019;17(3):221-227. doi:10.1080/ 2090598X.2019.1600990
7. Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12B):19M-23M. doi:10.1016/j.amjcard. 2005.07.006
8. Bouhanick B, Blacher J, Huyghe E. Sexual dysfunction and antihypertensive treatment: involvement of the different therapeutic classes and what to do about the treatment of hypertension. Presse Med. 2019;48(11 Pt 1):1222-8. doi:10.1016/j.lpm.2019.05.029
9. Aydın F, Bektur S, Taşdelen Y, et al. How does ivabradine effect erectile dysfunction in patients with heart failure? Kardiol Pol. 2017;75(9):893-898. doi:10.5603/KP.a2017.0095
10. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
11. Codolosa JN, Acharjee S, Figueredo VM. Update on ranolazine in the management of angina. Vasc Health Risk Manag. 2014;10:353-362. doi: 10.2147/VHRM.S40477
12. Cattaneo M, Porretta AP, Gallino A. Ranolazine: drug overview and possible role in primary microvascular angina management. Int J Cardiol. 2015;181:376-381. doi:10.1016/j.ijcard.2014.12.055
13. Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male. Philadelphia, PA: W.B. Saunders; 1948.
14. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460-463. doi:10. 1016/S0022-5347(05)67900-1
15. Rehberger-Likozar A, Šebeštjen M. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease. Coron Artery Dis. 2015;26(8):651-656. doi:10.1097/MCA. 0000000000000272
16. Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, et al. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev. 2017;2(2): CD011747. doi:10.1002/14651858.CD011747.pub2
17. Cappelleri JC, Rosen RC. The Sexual Health Inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005; 17(4):307-319. doi:10.1038/sj.ijir.3901327
18. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151(1):54-61. doi:10.1016/s0022-5347(17)34871-1
19. Sullivan ME, Thompson CS, Dashwood MR, et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease. Cardiovasc Res. 1999;43(3):658-665. doi:10.1016/s0008-6363(99) 00135-2
20. De Angelis L, Marfella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia. 2001;44(9): 1155-1160. doi:10.1007/s001250100616
21. Junemann KP, Aufenanger J, Konrad T, et al. The effect of impaired lipid metabolism on the smooth muscle cells of rabbits. Urol Res. 1991;19(5): 271-275. doi:10.1007/BF00299056
22. Baumhäkel M, Custodis F, Schlimmer N, et al. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE--knockout mice. Atherosclerosis. 2010;212(1):55-62, doi:10.1016/j.atherosclerosis.2010.03.002
23. Deshmukh SH, Patel SR, Pinassi E, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009;20(5):343-347. doi:10.1097/MCA.0b013e32832a198b
24. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802-1813. doi: 10.1056/NEJM200006153422407
25. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovas- cular patient: endothelial dysfunction is the common denominator. Heart. 2003;89(3):251-253. doi:10.1136/heart.89.3.251
26. Aldakkak M, Camara AK, Heisner JS, et al. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011;64(4):381-392. doi:10.1016/j.phrs.2011.06.018
27. Pérez FR, Venegas F, González M, et al. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension. 2009;53(6):1000-1007. doi:10.1161/HYPERTENSIONAHA.108.128520
Article available in :
Volume 3, Issue 1, 2025
Page : 5-9
https://doi.org/10.51271/JCCVS-0048
Article Information
Received : 24 Oca 2025
Accepted : 17 Mar 2025
Published : 27 Mar 2025
Corresponding Author :

Özge Turgay Yıldırım: Department of Cardiology, Eskişehir City Hospital, Eskişehir, Turkiye

[email protected]
Citation : Turgay Yıldırım Ö, Aydın F, Akşit E, Hüseyinoğlu Aydın A, Dişikırık T, Özgeyik M. The effect of ranolazine on erectile dysfunction in coronary artery disease patients. J Cardiol Cardiovasc Surg. 2025;3(1):5-9.

Read: 69
Cited: 0
Download : 67
_Footer